Canada Health Government has approved the drug TEMODAL in combination with Radiotherapy for treating patients with glioblastoma multiforme brain cancer. The drug TEMODAL that contains Temozolomide is produced by Schering-Plough Corporation and is used in treating two forms of brain cancer Glioblastoma multiforme and anaplastic astrocytoma. Clinical study using the drug TEMODAL was tested on newly diagnosed glioblastoma multiforme patients by researchers from National Cancer Institute, Canada and European organization for Research and Treatment of Cancer and they found the drug to be effective in controlling the growth of malignant cells in the brain, by producing cytotoxic effect on cancer cells and prevents replication and production of cancer cells. Researchers have found on a clinical study on 573 patients that a combination of drug TEMODAL and radiotherapy in brain cancer patients reduces the tumor burden and significantly increases the survival of the cancer patients. The drug has been shown very effective but is found to cause mild side effects of myelosuppression in patients and the researchers have reported the results of their study in the Journal the New England Journal of Medicine. << FDA Approves Novel Creation of Imitrex® Injection for Migrai... FDA approves CLARINEX-D 12 HOUR for seasonal allergic rhinit... >> Recommended Reading Drug Toxicity Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a drug, reaction to a drug or drug abuse. READ MORE Hodgkins Lymphoma Hodgkins lymphoma or Hodgkins disease has the distinction of being the first cancer to be cured by chemotherapy or by radiotherapy. READ MORE Non-Hodgkins Lymphoma Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of subtypes. READ MORE Parkinsons Disease Parkinson’s disease is a neurodegenerative disease caused by progressive dopamine brain cells loss. Symptoms of Parkinson’s disease are correctable to an extent. READ MORE Radiotherapy A detailed account of radiation, its mode of action, side effects and dosage in the treatment of cancer. READ MORE Most Popular on Medindia Hearing Loss Calculator Vent Forte (Theophylline) Drug Interaction Checker More News on: Drug ToxicityParkinsons DiseaseRadiotherapyCancer and HomeopathyParkinsons Disease Surgical TreatmentHodgkins LymphomaNon-Hodgkins LymphomaSignature Drug ToxicityCancer FactsCancer
Canada Health Government has approved the drug TEMODAL in combination with Radiotherapy for treating patients with glioblastoma multiforme brain cancer. The drug TEMODAL that contains Temozolomide is produced by Schering-Plough Corporation and is used in treating two forms of brain cancer Glioblastoma multiforme and anaplastic astrocytoma. Clinical study using the drug TEMODAL was tested on newly diagnosed glioblastoma multiforme patients by researchers from National Cancer Institute, Canada and European organization for Research and Treatment of Cancer and they found the drug to be effective in controlling the growth of malignant cells in the brain, by producing cytotoxic effect on cancer cells and prevents replication and production of cancer cells. Researchers have found on a clinical study on 573 patients that a combination of drug TEMODAL and radiotherapy in brain cancer patients reduces the tumor burden and significantly increases the survival of the cancer patients. The drug has been shown very effective but is found to cause mild side effects of myelosuppression in patients and the researchers have reported the results of their study in the Journal the New England Journal of Medicine.
